ALMS Quote, Financials, Valuation and Earnings

Lexeo Therapeutics has a net margin of -- compared to Alumis's net margin of --. Alumis's return on equity of -- beat Lexeo Therapeutics's return on equity of --.

Alumis has a consensus price target of $21.50, signalling upside risk potential of 382.06%. On the other hand Lexeo Therapeutics has an analysts' consensus of $20.57 which suggests that it could grow by 626.91%. Given that Lexeo Therapeutics has higher upside potential than Alumis, analysts believe Lexeo Therapeutics is more attractive than Alumis.

Alumis has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lexeo Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alumis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexeo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alumis pays -- of its earnings as a dividend. Lexeo Therapeutics pays out -- of its earnings as a dividend.

Alumis quarterly revenues are --, which are smaller than Lexeo Therapeutics quarterly revenues of --. Alumis's net income of -$94.8M is lower than Lexeo Therapeutics's net income of -$25.9M. Notably, Alumis's price-to-earnings ratio is -- while Lexeo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alumis is -- versus -- for Lexeo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

23andMe Holding has a net margin of -- compared to Alumis's net margin of --. Alumis's return on equity of -- beat 23andMe Holding's return on equity of --.

Alumis has a consensus price target of $21.50, signalling upside risk potential of 382.06%. On the other hand 23andMe Holding has an analysts' consensus of -- which suggests that it could grow by 225%. Given that Alumis has higher upside potential than 23andMe Holding, analysts believe Alumis is more attractive than 23andMe Holding.

Alumis has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison 23andMe Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alumis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 23andMe Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alumis pays -- of its earnings as a dividend. 23andMe Holding pays out -- of its earnings as a dividend.

Alumis quarterly revenues are --, which are smaller than 23andMe Holding quarterly revenues of --. Alumis's net income of -$94.8M is higher than 23andMe Holding's net income of --. Notably, Alumis's price-to-earnings ratio is -- while 23andMe Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alumis is -- versus 0.08x for 23andMe Holding. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Alumis's net margin of 32.71%. Alumis's return on equity of -- beat Merck &'s return on equity of 39.02%.

Alumis has a consensus price target of $21.50, signalling upside risk potential of 382.06%. On the other hand Merck & has an analysts' consensus of $104.67 which suggests that it could grow by 36.6%. Given that Alumis has higher upside potential than Merck &, analysts believe Alumis is more attractive than Merck &.

Alumis has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Alumis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.12% to investors and pays a quarterly dividend of $0.81 per share. Alumis pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alumis quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Alumis's net income of -$94.8M is lower than Merck &'s net income of $5.1B. Notably, Alumis's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alumis is -- versus 3.04x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Acelyrin has a net margin of -- compared to Alumis's net margin of --. Alumis's return on equity of -- beat Acelyrin's return on equity of --.

Alumis has a consensus price target of $21.50, signalling upside risk potential of 382.06%. On the other hand Acelyrin has an analysts' consensus of $8.00 which suggests that it could grow by 282.78%. Given that Alumis has higher upside potential than Acelyrin, analysts believe Alumis is more attractive than Acelyrin.

Alumis has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Acelyrin has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alumis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acelyrin offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alumis pays -- of its earnings as a dividend. Acelyrin pays out -- of its earnings as a dividend.

Alumis quarterly revenues are --, which are smaller than Acelyrin quarterly revenues of --. Alumis's net income of -$94.8M is lower than Acelyrin's net income of -$79M. Notably, Alumis's price-to-earnings ratio is -- while Acelyrin's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alumis is -- versus -- for Acelyrin. Usually stocks with elevated PS ratios are considered overvalued.